OncLive SOSS

Authors

Giuseppe Barbesino, MD

Latest:

Novel Treatment Advances in Differentiated Thyroid Cancer

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Matthew Brunner, MD

Latest:

Dr Brunner on the Heterogeneity of Relapsed Multiple Myeloma

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Matthew A. Lunning, DO, FACP

Latest:

CAR T-cells as Third-line and Beyond Therapy for FL

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Christopher Pleyer, MD

Latest:

Dr. Pleyer on Next Steps With Ibrutinib Plus Short-Course Fludarabine in Previously Untreated CLL

Christopher Pleyer, MD, discusses the next steps with the combination of ibrutinib and short-course fludarabine in previously untreated chronic lymphocytic leukemia.

Cora Sternberg, MD, FACP, Weill Cornell Medicine

Latest:

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

Jane Delartigue, PhD

Latest:

Tumor Agnostic Role of TMB Biomarker Faces Challenges

Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.

Abramson Cancer Center

Latest:

Julia “Julie” Borrelli Named Chair of the Abramson Cancer Center Director's Leadership Council

Julia “Julie” Borrelli has been appointed chair of the Abramson Cancer Center Director's Leadership Council.

Jean-Marie Michot, MD

Latest:

Dr. Michot on the Examination of CC-99282 in Relapsed/Refractory NHL

Jean-Marie Michot, MD, discusses the examination of CC-99282 in relapsed/refractory non–Hodgkin lymphoma.

Abdul Rafeh Naqash, MD

Latest:

Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC

Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.

Michael Foote, MD

Latest:

Dr Foote on the Ongoing Debate Over Upfront EGFR Inhibitor Use in CRC

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

Christine Mauz-Koerholz, MD, PhD

Latest:

Dr Mauz-Koerholz on the Role of Pembrolizumab in Younger Patients With Low-Risk Classic Hodgkin Lymphoma

Christine Mauz-Koerholz, MD, PhD, discusses updated results from the phase 2 KEYNOTE-667 trial, which were shared at the 2024 ASH Annual Meeting.

Yvonne Efebera, MD, Ohio State University Comprehensive Cancer Center

Latest:

Improving Management of Relapsed/Refractory Multiple Myeloma

Ewa Kalinka, MD, PhD

Latest:

Dr Kalinka on Frontline BMS-986012 Plus Nivolumab and Chemotherapy in ES-SCLC

Ewa Kalinka, MD, PhD, discusses interim phase 2 data with frontline BMS-986012 plus nivolumab and chemotherapy in extensive-stage small cell lung cancer.

Paul V. Viscuse, MD

Latest:

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

Melissa A. Simon, MD

Latest:

Dr. Simon on Ensuring Health Equity in Cancer Care

Melissa A. Simon, MD, discusses ensuring health equity in cancer care.

Shirley D'Sa, MD, FRCP, FRCPath

Latest:

Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study

Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström macroglobulinemia, including those with high-risk genetic mutations.

Jacob N. Stein, MD, MPH

Latest:

From Anguish to Action: Turning Despair Into Efforts to Improve Racial Equity

Oncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.

Changchun Deng, MD, PhD

Latest:

Dr Deng on the Evolution of the Hodgkin Lymphoma Treatment Paradigm

Changchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.

Veronika Bachanova, MD, PhD

Latest:

Dr. Bachanova on NK Cell Therapy in NHL

Veronika Bachanova, MD, PhD, discusses findings from a spatial analysis of the tumor microenvironment in patients with non-Hodgkin lymphoma who received and responded to adoptive natural killer cell therapy.

Natalia Neparidze, MD

Latest:

Dr Neparidze on the Implications of Early Data for Belantamab Mafodotin Plus Elotuzumab in R/R Myeloma

Natalia Neparidze, MD, discusses clinical implications and future of belantamab mafodotin and elotuzumab in heavily pretreated, relapsed/refractory multiple myeloma.